5 Key Takeaways

• 1

  Emerging novel therapeutics for dermatomyositis and cutaneous lupus erythematosus are generating excitement among experts.

• 2

  A novel intravenous immune globulin preparation approved by the FDA in 2021 showed significant improvement in dermatomyositis patients.

• 3

  Janus kinase inhibitors tofacitinib, brepocitinib, and baricitinib may reduce disease severity in treatment-naive dermatomyositis.

• 4

  Deucravacitinib, an oral tyrosine kinase 2 inhibitor, demonstrated significant improvement in cutaneous lupus erythematosus patients.

• 5

  Anifrolumab, approved by the FDA in 2021, has shown efficacy in refractory cutaneous lupus, with further studies planned.